Antimycobacterial Agents: Combating Drug-Resistant Tuberculosis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2982
Special Issue Editor
Interests: medicinal chemistry; structure–activity relationship; privileged scaffold; novel synthetic methodology; mycobacteria; cannabinoids; brain cancer; neurodegeneration; neuroinflammation
Special Issue Information
Dear Colleagues,
Tuberculosis (TB) remained the leading cause of death caused by infection until it was overtaken by SARS-CoV-2. The causative agent, Mycobacterium tuberculosis, is known to be highly effective in staying dormant within the human host, and when the time is right—often coinciding with the host’s immune system being compromised—it will cause the development of the disease phenotype. Similarly to what we have witnessed with the resistance observed for COVID-19 variants, multi-drug- and extensively drug-resistant forms of TB necessitate novel treatment and preventative options. A lot still needs to be uncovered regarding aspects of TB host–bacteria interplay and combating the resistant forms. The vaccine has played a key role in providing immunity worldwide since its discovery around a century ago. However, much like what we have seen with COVID-19 vaccines, both preventative and treatment options are crucial for healthcare. This is when medicinal chemists and pharmacologists from academic, open-source and pharma settings have a role to play: small-molecule drugs will continue to provide essential ammunition for human medicine. With this background in mind, I would like to invite you to contribute towards our Special Issue entitled “Antimycobacterial Agents: Combating Drug-Resistant Tuberculosis” with Pharmaceutics (IF = 5.215). The following points represent broad areas of interest that papers submitted to this Special Issue may cover:
- All aspects within the definition of medicinal chemistry related to the invention, discovery, design, identification and preparation of antimycobacterial compounds, the study of their binding and/or functional activities, metabolism/ADMET, the interpretation of their mode of action at the molecular level and the construction of structure–activity relationships;
- Novel strategies and synthetic methodologies with relevant application to mycobacterial chemical biology and medicinal chemistry;
- We aim to publish updated reviews as well as research articles with comprehensive theoretical and experimental details covering all aspects of small molecules as drug candidates, e.g., drug discovery and design, combinatorial chemistry, structure-property correlations, molecular modelling and bioinformatics. Short communications are also accepted; therefore, there is no restriction on the length of a paper.
I look forward to receiving your exciting scientific findings.
Dr. Hendra Gunosewoyo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- medicinal chemistry
- structure–activity relationship
- genomics
- transcriptomics
- proteomics
- mycobacteria
- tuberculosis
- drug resistance
- latent tuberculosis
- Mycobacterium abscessus
- drug repurposing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
